Advertisement
ABBV or IONS or ZTS
Which Stock Would AI Choose? AbbVie (ABBV) vs. Ionis Pharmaceuticals (IONS) vs. Zoetis (ZTS) Stock Comparison
Key Takeaways
- ABBV demonstrates resilience with immunology drugs like Skyrizi and Rinvoq offsetting Humira declines, showing modest recent gains amid a strong pipeline in oncology and neuroscience.
- IONS exhibits high volatility with over 100% one-year returns but recent pullbacks, driven by RNA-targeted therapies for rare neurological and cardiovascular diseases.
- ZTS faces short-term pressure with monthly declines around 8%, yet analysts highlight undervaluation in the animal health sector with robust fundamentals.
- All three stocks operate in healthcare but diverge in focus: biopharma giants versus biotech innovator and animal health leader, influencing risk-reward profiles.
- Recent market activity shows ABBV with relative stability, while IONS and ZTS reflect biotech sector swings.
- Valuation metrics suggest potential opportunities, with analyst targets implying upside across the board in relative performance comparisons.
Introduction
This stock comparison examines ABBV, IONS, and ZTS, three healthcare equities spanning human biopharmaceuticals and animal health. Investors seeking exposure to immunology, rare disease therapies, and veterinary innovations may find value here, particularly amid sector rotations and pipeline advancements. Traders focused on relative performance will note contrasts in momentum, volatility, and growth drivers in the current market environment, where biotech sentiment fluctuates with clinical updates and economic pressures. This analysis highlights key metrics for informed positioning.
ABBV Overview and Recent Performance
AbbVie Inc. (ABBV), a research-based biopharmaceutical leader, focuses on immunology, oncology, neuroscience, and aesthetics. Key products include Skyrizi and Rinvoq for autoimmune conditions, alongside Venclexta and Elahere in oncology. Post-Humira patent cliffs, the company has transitioned successfully, with immunology sales projected to exceed $30 billion by 2027.
In recent market activity, ABBV shares have shown stability, with weekly dips offset by year-to-date resilience around flat to slightly negative. Influences include positive Phase 3 data for pipeline expansions and analyst upgrades citing a 20%+ rebound in 2025. Sentiment benefits from a robust dividend and extensive late-stage trials, though competition in immunology tempers gains. Trading near $220, the stock reflects steady institutional interest.
IONS Overview and Recent Performance
Ionis Pharmaceuticals Inc. (IONS), a biotechnology pioneer in RNA-targeted therapies, develops treatments for neurological, cardiovascular, and rare diseases. Marketed products include Wainua for ATTRv-PN, Spinraza for spinal muscular atrophy via Biogen partnership, and Qalsody for ALS. Its pipeline features antisense drugs like olezarsen for hypertriglyceridemia.
Recent weeks have seen IONS pull back amid broader biotech volatility, with monthly declines near 10% despite over 110% one-year gains. Q4 revenue beat estimates at $203 million, fueled by commercial launches, positively influencing sentiment. However, high beta and clinical risks contribute to swings, with shares around $70 reflecting pipeline promise against execution uncertainties.
ZTS Overview and Recent Performance
Zoetis Inc. (ZTS), the global leader in animal health, provides vaccines, medicines, diagnostics, and biodevices for companion animals and livestock. Core offerings target parasiticides, dermatology, and anti-infectives across dogs, cats, cattle, and poultry, generating $9.5 billion in projected revenue.
ZTS has underperformed recently, with 8% monthly drops and year-to-date weakness around 7%, trading near $118. Factors include sector headwinds and investor stake reductions, yet analysts note undervaluation with fair value estimates above $150. Strong fundamentals and raised earnings outlooks support potential reversal, buoyed by innovation in precision animal health.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the platform's top-performing AI trading bots, curated from over 350 total bots that trade thousands of tickers across stocks, ETFs, and crypto. AI analyzes performance in volatile conditions to spotlight 25 trending ones suited to current markets, featuring strategies like swing trading, trend following, and hedging. Top bots deliver annualized returns from 17% to over 200%, win rates up to 95%, and profit factors exceeding 25, with timeframes from 5 minutes to 62 days. Examples include bots targeting semiconductors (SOXL) at +119% annualized and biotechnology (BIB) at 95% win rates. These diverse bots—spanning technical, fundamental, and volatility-based approaches—offer copy-trading options via signal, virtual, or brokerage agents. Explore Trending AI Robots to identify tools aligning with your style.
Head-to-Head Comparison
ABBV, IONS, and ZTS share healthcare exposure but contrast sharply in business models: ABBV's diversified biopharma scale versus IONS' biotech focus on RNA innovation and ZTS' niche animal health dominance.
Growth drivers differ: ABBV leverages immunology blockbusters and a 20+ Phase III pipeline; IONS bets on rare disease approvals amid partnerships; ZTS expands via companion animal demand. Recent momentum favors ABBV's stability over peers' volatility.
Risk factors include IONS' clinical binary events and ZTS' regulatory hurdles, versus ABBV's competition. Sector-wise, human pharma meets animal care resilience. Valuation sensitivity shows ZTS potentially undervalued, while sentiment tilts toward ABBV's dividend appeal amid biotech caution.
Tickeron AI Verdict
Tickeron’s AI currently favors ABBV for its trend consistency, post-Humira stability, and catalyst-rich pipeline positioning it ahead in relative strength. While IONS offers upside from RNA breakthroughs and ZTS undervaluation potential, ABBV's lower volatility and earnings trajectory suggest higher probability of near-term outperformance in the healthcare space.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ABBV’s FA Score shows that 2 FA rating(s) are green whileIONS’s FA Score has 0 green FA rating(s), and ZTS’s FA Score reflects 2 green FA rating(s).
- ABBV’s FA Score: 2 green, 3 red.
- IONS’s FA Score: 0 green, 5 red.
- ZTS’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ABBV’s TA Score shows that 6 TA indicator(s) are bullish while IONS’s TA Score has 4 bullish TA indicator(s), and ZTS’s TA Score reflects 4 bullish TA indicator(s).
- ABBV’s TA Score: 6 bullish, 4 bearish.
- IONS’s TA Score: 4 bullish, 5 bearish.
- ZTS’s TA Score: 4 bullish, 6 bearish.
Price Growth
ABBV (@Pharmaceuticals: Major) experienced а +1.70% price change this week, while IONS (@Biotechnology) price change was +2.19% , and ZTS (@Pharmaceuticals: Generic) price fluctuated +1.74% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.87%. For the same industry, the average monthly price growth was -3.24%, and the average quarterly price growth was +6.57%.
The average weekly price growth across all stocks in the @Biotechnology industry was +2.26%. For the same industry, the average monthly price growth was -2.98%, and the average quarterly price growth was +6.73%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +3.55%. For the same industry, the average monthly price growth was +3.94%, and the average quarterly price growth was -0.03%.
Reported Earning Dates
ABBV is expected to report earnings on Apr 29, 2026.
IONS is expected to report earnings on May 06, 2026.
ZTS is expected to report earnings on May 07, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (-0.87% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
@Biotechnology (+2.26% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
@Pharmaceuticals: Generic (+3.55% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
| ABBV | IONS | ZTS | |
| Capitalization | 376B | 12.6B | 50.5B |
| EBITDA | 17.6B | -273.12M | 4.07B |
| Gain YTD | -6.294 | -3.388 | -4.226 |
| P/E Ratio | 89.62 | N/A | 19.93 |
| Revenue | 61.2B | 944M | 9.47B |
| Total Cash | 5.26B | 2.68B | 2.31B |
| Total Debt | 67.5B | 2.07B | 9.24B |
ABBV | IONS | ZTS | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 61 | 69 | 7 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 38 Fair valued | 100 Overvalued | 30 Undervalued | |
PROFIT vs RISK RATING 1..100 | 13 | 56 | 100 | |
SMR RATING 1..100 | 1 | 98 | 16 | |
PRICE GROWTH RATING 1..100 | 59 | 41 | 61 | |
P/E GROWTH RATING 1..100 | 40 | 72 | 85 | |
SEASONALITY SCORE 1..100 | 4 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ZTS's Valuation (30) in the Pharmaceuticals Generic industry is in the same range as ABBV (38) in the Pharmaceuticals Major industry, and is significantly better than the same rating for IONS (100) in the Biotechnology industry. This means that ZTS's stock grew similarly to ABBV’s and significantly faster than IONS’s over the last 12 months.
ABBV's Profit vs Risk Rating (13) in the Pharmaceuticals Major industry is somewhat better than the same rating for IONS (56) in the Biotechnology industry, and is significantly better than the same rating for ZTS (100) in the Pharmaceuticals Generic industry. This means that ABBV's stock grew somewhat faster than IONS’s and significantly faster than ZTS’s over the last 12 months.
ABBV's SMR Rating (1) in the Pharmaceuticals Major industry is in the same range as ZTS (16) in the Pharmaceuticals Generic industry, and is significantly better than the same rating for IONS (98) in the Biotechnology industry. This means that ABBV's stock grew similarly to ZTS’s and significantly faster than IONS’s over the last 12 months.
IONS's Price Growth Rating (41) in the Biotechnology industry is in the same range as ABBV (59) in the Pharmaceuticals Major industry, and is in the same range as ZTS (61) in the Pharmaceuticals Generic industry. This means that IONS's stock grew similarly to ABBV’s and similarly to ZTS’s over the last 12 months.
ABBV's P/E Growth Rating (40) in the Pharmaceuticals Major industry is in the same range as IONS (72) in the Biotechnology industry, and is somewhat better than the same rating for ZTS (85) in the Pharmaceuticals Generic industry. This means that ABBV's stock grew similarly to IONS’s and somewhat faster than ZTS’s over the last 12 months.
| ABBV | IONS | ZTS | |
|---|---|---|---|
| RSI ODDS (%) | 1 day ago 33% | 1 day ago 73% | 1 day ago 55% |
| Stochastic ODDS (%) | 1 day ago 68% | 1 day ago 69% | 1 day ago 62% |
| Momentum ODDS (%) | 1 day ago 62% | 1 day ago 69% | 1 day ago 52% |
| MACD ODDS (%) | 1 day ago 60% | 1 day ago 68% | 1 day ago 69% |
| TrendWeek ODDS (%) | 1 day ago 47% | 1 day ago 71% | 1 day ago 57% |
| TrendMonth ODDS (%) | 1 day ago 51% | 1 day ago 74% | 1 day ago 63% |
| Advances ODDS (%) | 1 day ago 57% | 1 day ago 67% | 1 day ago 52% |
| Declines ODDS (%) | 3 days ago 47% | 3 days ago 65% | 14 days ago 58% |
| BollingerBands ODDS (%) | 1 day ago 50% | 1 day ago 69% | 1 day ago 59% |
| Aroon ODDS (%) | 1 day ago 45% | 1 day ago 60% | 1 day ago 65% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| MRAL | 3.97 | 0.15 | +3.93% |
| GraniteShares 2x Long MARA Daily ETF | |||
| DRN | 9.82 | 0.22 | +2.29% |
| Direxion Daily Real Estate Bull 3X ETF | |||
| GDXW | 57.76 | 0.12 | +0.21% |
| Roundhill Gold Miners Weeklypay ETF | |||
| EIDO | 15.87 | -0.02 | -0.13% |
| iShares MSCI Indonesia ETF | |||
| HFXI | 35.29 | -0.25 | -0.70% |
| NYLI FTSE International Eq Ccy Netrl ETF | |||
ABBV and
Correlation & Price change
A.I.dvisor indicates that over the last year, ABBV has been loosely correlated with BMY. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if ABBV jumps, then BMY could also see price increases.
| Ticker / NAME | Correlation To ABBV | 1D Price Change % | ||
|---|---|---|---|---|
| ABBV | 100% | +0.38% | ||
| BMY - ABBV | 58% Loosely correlated | +0.46% | ||
| PFE - ABBV | 57% Loosely correlated | -0.91% | ||
| BIIB - ABBV | 55% Loosely correlated | -1.55% | ||
| AMGN - ABBV | 53% Loosely correlated | +1.66% | ||
| NVS - ABBV | 52% Loosely correlated | +0.41% | ||
More | ||||
IONS and
Correlation & Price change
A.I.dvisor indicates that over the last year, IONS has been closely correlated with CYTK. These tickers have moved in lockstep 67% of the time. This A.I.-generated data suggests there is a high statistical probability that if IONS jumps, then CYTK could also see price increases.
| Ticker / NAME | Correlation To IONS | 1D Price Change % | ||
|---|---|---|---|---|
| IONS | 100% | +1.93% | ||
| CYTK - IONS | 67% Closely correlated | -1.79% | ||
| MLYS - IONS | 66% Closely correlated | -2.13% | ||
| ARWR - IONS | 49% Loosely correlated | +2.92% | ||
| MNKD - IONS | 48% Loosely correlated | -1.53% | ||
| IDYA - IONS | 47% Loosely correlated | +0.13% | ||
More | ||||
ZTS and
Correlation & Price change
A.I.dvisor indicates that over the last year, ZTS has been loosely correlated with ELAN. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if ZTS jumps, then ELAN could also see price increases.
| Ticker / NAME | Correlation To ZTS | 1D Price Change % | ||
|---|---|---|---|---|
| ZTS | 100% | +0.20% | ||
| ELAN - ZTS | 52% Loosely correlated | -0.59% | ||
| VTRS - ZTS | 44% Loosely correlated | +0.26% | ||
| PRGO - ZTS | 41% Loosely correlated | -2.12% | ||
| PAHC - ZTS | 39% Loosely correlated | +0.78% | ||
| HLN - ZTS | 39% Loosely correlated | +0.40% | ||
More | ||||